GLPwatch
Papers (9189)
Page 140 of 154, ranked by citation count.
- Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials.
- [Cardiovascular Effects of Antidiabetic Therapies].
- Liraglutide versus colesevelam for treating bile acid diarrhoea.
- Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.
- THR-β Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty.
- Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
- Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes.
- Comparative efficacy of GLP-1 RA, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: A network meta-analysis.
- Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach.
- Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
- Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.
- GLP-1RA partially alleviates obesity-induced reproductive dysfunction driven by the interplay mechanisms of inflammation and metabolic dysregulation via the SIRT-associated pathway.
- [A meta-analysis of efficacy and safety of anti-obesity medications in the treatment of childhood obesity].
- [Semaglutide 2.4 mg (Wegovy®) for the management of clinical obesity with weight-related complications].
- Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes.
- The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials.
- Effect of GLP-1 receptor agonists on idiopathic intracranial hypertension: A systematic review.
- Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.
- Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- GLP-1 receptor agonist utilization is associated with a low risk of Anesthesia-related complications prior to total joint arthroplasty.
- SOUL searching in GLP-1 therapy: Oral semaglutide confirms cardioprotection in type 2 diabetes.
- Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.
- Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with Cushing’s syndrome: a multicenter retrospective study.
- Semaglutide (Wegovy) for weight loss.
- Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study.
- Pharmacist-led management of GLP-1 and GIP/GLP-1 receptor agonists in type 2 diabetes mellitus.
- Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus.
- The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease.
- Web Exclusive. Annals On Call - Dulaglutide, Semaglutide, and Tirzepatide: How Do Gastrointestinal Adverse Effects Compare?
- Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes.
- A Validated, Stability-Indicating HPLC Method for the Simultaneous Determination of Five Related Substances in Liraglutide Drug Substance.
- GLP-1 receptor agonists on WHO-EML 2025 list: major breakthrough bounded by persistent challenge.
- Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis.
- Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review.
- Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review.
- [Weight reducing and glucose reducing effects of liraglutide treatment for patients with type 2 diabetes].
- Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs.
- [Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
- Reframing polycystic ovary syndrome as a complication of obesity: the evolving role of incretin-based therapies.
- Liraglutid verzögert Diabetesentstehung.
- Drugs and devices for weight management.
- Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes.
- [GLP-1 receptor agonists in hypertension - a new approach for difficult-to-treat blood pressure?]
- Benchmarking the medication efficiency and technological progress of diabetes drugs.
- New drugs for weight loss: Why change in body composition matters and why nutrition and exercise remain paramount.
- [Obesity: novel pharmacological treatments].
- Corrigendum to Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
- Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study.
- Effect of tirzepatide on prediabetics and blood pressure with implications for future research.
- Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis.
- Semaglutide use in a patient with a long-term ileostomy: A case report highlighting clinical risks and evidence gaps.
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
- Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study.
- In brief: Removal of suicidality warning from GLP-1 Agonists for weight management.
- A cardiovascular indication for oral semaglutide (Rybelsus).
- Oral semaglutide (Wegovy) for weight loss.
- Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States.
- The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review.
- GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study.